OncoMatch/Clinical Trials/NCT06528301
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Is NCT06528301 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies rapamycin for lymphoma, b-cell.
Treatment: rapamycin — This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: CD19 expression
Patients who have previously received CD19-directed therapy must have biopsy confirming CD19 expression following completion of prior CD19-directed therapy.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: allogeneic bone marrow transplant
Cannot have received: gene therapy
Cannot have received: adoptive cell transfer
Exception: car t-cell therapy in car t-exposed subjects
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- The David and Etta Jonas Center for Cellular Therapy · Chicago, Illinois
- Washington University School of Medicine/Siteman Cancer Center · St Louis, Missouri
- University of Nebraska Medical Center · Omaha, Nebraska
- University of Cincinnatti Medical Center · Cincinnati, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06528301 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic bone marrow transplant, gene therapy, adoptive cell transfer disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify